DexCom, Inc. DXCM reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus ...

DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly ...

Dexcom reports 13% Q4 revenue growth to $1.26B, beating analyst expectations despite mixed analyst ratings and competitive pressures.

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for ...

DexCom (NASDAQ: DXCM) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, ...

Shares of DexCom Inc. advanced 7.59% to $70.02 Friday, on what proved to be an all-around positive trading session for the ...

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

DexCom reported worldwide revenue of $1.26 billion versus $1.11 billion a year earlier, marking 13% reported growth and 12% organic. U.S. Q4 revenue climbed 11% year over year to $892 million, while ...

In addition to Jefferies, Dexcom also received a Buy from Canaccord Genuity’s William Plovanic in a report issued today. However, on the same day, Barclays maintained a Sell rating on Dexcom (NASDAQ: ...

Dexcom announced a new wave of AI-powered features designed to help users understand how food and daily habits affect their metabolic health.

Shares of DexCom rose after higher revenue in the fourth quarter boosted the company's profit. The stock was up 9% to $70.96 in Friday afternoon trading. Shares have fallen 16% over the past 12 months ...